Remove Drugs Remove Licensing Remove Therapies
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. The drug earned Novartis more than $1.3 You can unsubscribe at anytime. subsidiary EMD Serono Inc.,

Drugs 130
article thumbnail

Biogen strikes RNAi deal with City; Aurion withdraws IPO

BioPharma Drive: Drug Pricing

Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug. City will receive $46 million from Biogen under the alliance.

Licensing 179
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Verdiva starts up with $411M and a portfolio of obesity drugs from China

BioPharma Drive: Drug Pricing

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind Biosciences, led by an oral therapy ready for Phase 2 testing.

Licensing 254
article thumbnail

Novavax sells Czech plant to Novo; Relay licenses out a cancer drug

BioPharma Drive: Drug Pricing

Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy. Novo will pay $200 million to gain control of the protein manufacturing factory.

Licensing 141
article thumbnail

AbbVie gets into obesity with $350M deal for once-weekly shot

BioPharma Drive: Drug Pricing

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

Licensing 193
article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates.

Drugs 65
article thumbnail

Obesity care gets personalised: tailoring therapies with Phenomix

Drug Target Review

In this interview, Bagnall explains how this approach is improving patient outcomes and driving the development of better obesity drugs. Knowing a patients subtype or phenotype can be used to guide obesity treatments of all kinds, including drug therapy, devices, bariatric surgery and even diet and lifestyle interventions, Bagnall explains.